AbbVie (ABBV) financial statements

+250.6%since 2011
FY2025 revenue
$61.2B▲ +8.6%
FY2025 net income
$4.2B▼ −1.2%
FY2025 diluted EPS
$2.36▼ −1.3%
FY2025 free cash flow
$17.8B▼ −0.1%

AbbVie income statement

AbbVie income statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue61,16056,33454,318
Operating income15,0759,13712,757
Pretax income6,5973,7166,250
Net income4,2264,2784,863
Diluted earnings per share2.362.392.72

AbbVie balance sheet

AbbVie balance sheet
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents5,2295,52412,814
Total assets133,960135,161134,711
Total liabilities (derived)137,188131,797124,314
Total equity-3,2283,36410,397
Long-term debt58,94160,34052,194

AbbVie cash flow statement

AbbVie cash flow statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow19,03018,80622,839
Capital expenditure-1,214-974-777
Free cash flow (derived)17,81617,83222,062
Dividends paid-11,657-11,025-10,539
Share repurchases-980-1,708-1,972

Quarterly highlights

Quarterly highlights
USD millionsQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025
Period ended30 Sep 202630 Jun 202631 Mar 202631 Dec 2025
Revenue17,40416,99015,00216,618
Operating income (derived)6,2676,4323,9904,544
Net income4,2183,6136951,816
Diluted earnings per share2.372.030.391.02
Operating cash flow (derived)7,6063,4363,8295,218
Total assets147,680135,115136,463133,960

AbbVie major shareholders

AbbVie major shareholders
HolderShare of classSharesFiled
Vanguard Capital Management7.5%132,924,05830 April 2026

AbbVie 10-K and SEC filings

AbbVie 10-K and SEC filings
FiledFormTypeDescription
3 November 202610-QQuarterly reportQuarterly report
2 November 20268-KCurrent reportFORM 8-K
30 October 20268-KCurrent reportCurrent report
15 October 20268-KCurrent reportFORM 8-K
5 October 20268-KCurrent reportCurrent report
3 September 20268-KCurrent reportFORM 8-K
18 August 20268-KCurrent reportFORM 8-K
5 August 20268-KCurrent reportFORM 8-K

Common questions

What was AbbVie's revenue in fiscal 2025?

AbbVie reported $61.2 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 8.6% from fiscal 2024.

What was AbbVie's net income in fiscal 2025?

AbbVie reported net income of $4.2 billion for fiscal 2025, the year ended 31 December 2025, down 1.2% from fiscal 2024. Diluted earnings per share were $2.36.

What was AbbVie's free cash flow in fiscal 2025?

AbbVie had $17.8 billion in free cash flow in fiscal 2025. Operating cash flow was $19.0 billion and capital expenditure was $1.2 billion.

What were AbbVie's total assets at the end of fiscal 2025?

AbbVie reported total assets of $134.0 billion at the end of fiscal 2025, the year ended 31 December 2025.

How much AbbVie history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.